Latest European Market News

Krakatoa Resources reports significant progress in drilling at its Zopkhito Antimony-Gold Project in Georgia, with most holes intersecting visible antimony mineralisation. Assay results are eagerly awaited to validate historical resource estimates and support a maiden JORC-compliant Mineral Resource.

Dyno Nobel Limited reported a robust 23% increase in EBIT for FY25, driven by strong explosives performance and transformation initiatives, while progressing its fertilisers separation and setting ambitious sustainability targets.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

DTI Group secures a major $2 million contract with Rio Tinto for autonomous locomotive tech and re-enters the European market through a new agreement with CAF.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

Little Green Pharma reported a robust September quarter with revenue exceeding $10 million, driven by growth across all product lines and strong European market performance. The company is poised to benefit from upcoming regulatory reforms and operational efficiencies.

Metals Australia Limited has reported a 3.3-fold increase in its Lac Carheil Graphite project resource, now totaling 50 million tonnes at 10.2% graphite content, while progressing key studies for a battery anode material plant in Quebec.